ERBB4: Receptor tyrosine-protein kinase erbB-4
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis.
- Drugs that act on it: 7
- Approved: 3
- In phases 1 to 3: 4
- Sponsors: 6
Who Is On It, and How Far Along
Every drug ChEMBL records acting on ERBB4, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
Approved3
Phase 31
Phase 21
Phase 12
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Pfizer229%
- ArriVent BioPharma, Inc.114%
- Bristol-Myers Squibb114%
- Daiichi Sankyo114%
- Johnson & Johnson114%
- Puma Biotechnology114%
Modalities
Drugs on this target by ChEMBL molecule type.
- Small molecule7100%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Receptor protein-tyrosine kinase erbB-4 inhibitor.| Neratinib | Approved | Puma Biotechnology | Small molecule | Inhibitor | — | 33 | — |
| Afatinib | Approved | ArriVent BioPharma, Inc. | Small molecule | Inhibitor | — | 28 | — |
| Dacomitinib anhydrous | Approved | Pfizer | Small molecule | Inhibitor | — | 0 | — |
| Canertinib | Phase 3 | Pfizer | Small molecule | Inhibitor | — | 0 | — |
| BMS-690514 | Phase 2 | Bristol-Myers Squibb | Small molecule | Inhibitor | — | 0 | — |
| AC-480 | Phase 1 | Daiichi Sankyo | Small molecule | Inhibitor | — | 0 | — |
| JNJ-26483327 | Phase 1 | Johnson & Johnson | Small molecule | Inhibitor | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Non-small cell lung carcinoma
- 0.68
- Neoplasm
- 0.61
- Cancer
- 0.61
- Breast cancer
- 0.56
- Abnormality of the skeletal system
- 0.55
- Medullary thyroid gland carcinoma
- 0.55
- Hereditary disease
- 0.51
- Breast carcinoma
- 0.49
- Lung adenocarcinoma
- 0.49
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- ERBB4
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3009, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q15303, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets